|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 187.49 USD | +3.61% |
|
-18.54% | -16.82% |
| 02-06 | UBS Adjusts Price Target on IQVIA to $240 From $280, Maintains Buy Rating | MT |
| 02-06 | Leerink Partners Adjusts Price Target on IQVIA Holdings to $228 From $256, Maintains Outperform Rating | MT |
Business description: Iqvia Holdings Inc.
- development of contract research and clinical development solutions and services (55.4%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes;
- development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers;
- integrated services (4.7%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc.
Net sales are distributed geographically as follows: Americas (47.8%), Europe and Africa (31.9%) and Asia/Pacific (20.3%).
Number of employees: 93,000
Sales by Activity: Iqvia Holdings Inc.
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
Research & Development Solutions | 5.76B | 7.56B | 7.92B | 8.4B | 8.53B |
Technology & Analytics Solutions (TAS) | 4.86B | 5.53B | 5.75B | 5.86B | 6.16B |
Contract Sales & Medical Solutions (CSMS) | 741M | 784M | 743M | 727M | 718M |
Geographical breakdown of sales: Iqvia Holdings Inc.
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
United States | 3.98B | 4.72B | 6.05B | 6.74B | 6.47B |
Europe and Africa | - | 4.36B | 4.37B | 4.46B | 4.92B |
Asia-Pacific | 2.24B | 2.67B | 3B | 2.97B | 3.13B |
Americas (Excl. United States) | 1.44B | 2.13B | 996M | 809M | 886M |
Europe and Africa (Excl. United Kingdom) | 2.56B | - | - | - | - |
United Kingdom | 1.14B | - | - | - | - |
Executive Committee: Iqvia Holdings Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Ari Bousbib
CEO | Chief Executive Officer | 65 | 02/10/2016 |
Ronald Bruehlman
DFI | Director of Finance/CFO | 65 | 31/07/2020 |
Jeffrey Spaeder
CTO | Chief Tech/Sci/R&D Officer | - | - |
James Berkshire
COO | Chief Operating Officer | 53 | 30/06/2017 |
W. Staub
CTO | Chief Tech/Sci/R&D Officer | 63 | 24/09/2023 |
Composition of the Board of Directors: Iqvia Holdings Inc.
| Director | Title | Age | Since |
|---|---|---|---|
John Leonard
BRD | Director/Board Member | 68 | 04/02/2015 |
John Connaughton
BRD | Director/Board Member | 60 | 31/12/2007 |
Ari Bousbib
CHM | Chairman | 65 | 02/10/2016 |
Todd Sisitsky
BRD | Director/Board Member | 54 | 31/12/2015 |
John Danhakl
BRD | Director/Board Member | 69 | 02/10/2016 |
Jim Fasano
BRD | Director/Board Member | 56 | 02/10/2016 |
Colleen Goggins
BRD | Director/Board Member | 70 | 26/07/2017 |
Carol Burt
BRD | Director/Board Member | 68 | 20/02/2019 |
Leslie Morris
BRD | Director/Board Member | 55 | 23/01/2022 |
Sheila Stamps
BRD | Director/Board Member | 68 | 25/01/2022 |
Company details: Iqvia Holdings Inc.
Group companies: Iqvia Holdings Inc.
| Name | Category and Sector |
|---|---|
Aecio IT Solutions India Pvt Ltd. | |
Aecio IT Solutions India Pvt Ltd. | |
IQVIA RDS (India) Pvt Ltd.
 IQVIA RDS (India) Pvt Ltd. Engages in research and development of medicine and medical apparatus | |
159 Technology Solutions Pvt Ltd. | |
IQVIA Analytics Services Pvt Ltd.
 IQVIA Analytics Services Pvt Ltd. Provides business and management consulting services |
Other Biotechnology & Medical Research
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.61% | -18.54% | -10.70% | -19.29% | 31.8B | |
| -0.19% | -1.49% | -15.63% | -7.11% | 46.82B | |
| +1.99% | +3.98% | +54.64% | +44.35% | 39.16B | |
| +1.15% | +4.76% | +26.41% | +44.46% | 32.9B | |
| +1.39% | +0.56% | +123.75% | +272.81% | 18.85B | |
| +0.14% | -6.94% | +50.16% | +133.97% | 15.27B | |
| -0.67% | -0.21% | +33.02% | -4.33% | 14.18B | |
| Average | +1.06% | -2.04% | +37.38% | +66.41% | 28.43B | |
| Weighted average by Cap. | +1.21% | -1.64% | +27.66% | +47.14% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- IQV Stock
- Company Iqvia Holdings Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition